Related Experiment Video
Updated: Aug 8, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Role of MTHFR C677T polymorphism in ischemic stroke
Inusha Panigrahi1, Tathagata Chatterjee, Arijit Biswas
1Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, Delhi - 110 029, India.
Neurology India
|May 9, 2006
Summary
The MTHFR C677T polymorphism, particularly homozygosity, is linked to high homocysteine levels and increased ischemic stroke risk in North Indians. Folate levels may influence the MTHFR TT genotype
Area of Science:
- Medical Genetics
- Neurology
- Cardiovascular Research
Background:
- The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with elevated homocysteine levels.
- Hyperhomocysteinemia is a recognized risk factor for thrombotic events, including ischemic stroke.
Purpose of the Study:
- To investigate the role of the MTHFR C677T polymorphism in North Indian individuals diagnosed with ischemic stroke.
- To assess the association between MTHFR C677T genotype, homocysteine levels, and ischemic stroke risk.
Main Methods:
- Prospective study recruiting ischemic stroke patients and healthy controls.
- Measurement of plasma homocysteine, serum folate, and Vitamin B12 levels.
- Detection of MTHFR C677T polymorphism using PCR-RFLP.
Main Results:
- 12.5% of ischemic stroke patients exhibited high homocysteine levels.
- Three of four patients with hyperhomocysteinemia were homozygous (TT) for the MTHFR C677T polymorphism.
- Low serum folate levels were observed in two of the three homozygous MTHFR TT genotype cases.
Conclusions:
- Primary hyperhomocysteinemia, largely due to MTHFR C677T homozygosity, is a significant risk factor for ischemic stroke in the North Indian population.
- Serum folate levels might modulate the clinical presentation associated with the MTHFR TT genotype.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...